Numinus Wellness Q2 2021 Results Highlighted by $17.25 Million Financing, Mindspace Wellbeing Acquisition and Clinical… Apr 30, 2021
In The Face of Emerging Research, Numinus’ Upcoming Phase One Trial Is All About Safety And Efficacy Apr 30, 2021
Numinus Announces Listing of Warrants and Change of Trading Symbol for Previously Listed Warrants Apr 26, 2021
Numinus Executives Dish on Details of Its Upcoming Phase 1 Clinical Trial Using Natural Psilocybin Apr 26, 2021
Numinus Science Officer Sharan Sidhu: We Won’t Patent IP That Makes Psychedelics Inaccessible Mar 19, 2021
